Grant Support

Current Grant Support

Christian Capitini, MD

Mario Otto, MD, PhD

Paul Sondel, MD, PhD

Midwest Athletes Against Childhood Cancer, “Prognostic markers and therapeutic targets in GATA2-related myelodysplastic syndromes and leukemia” (2017-2019). Hofmann, PI

EvansMDS, “Prognostic markers and therapeutic targets in GATA2-related myelodysplastic syndromes” (2017-2019). Hofmann, PI

Midwest Athletes Against Childhood Cancer, “Support for research data management” (2007-2019). DeSantes, PI

Midwest Athletes Against Childhood Cancer, “Treatment of relapsed or refractory neuroblastoma with ex-vivo activated and expanded haploidentical NK cells and continuous infusion Hu14.18-IL2” (2017-2019). DeSantes, PI

Children’s Hospital Los Angeles & NIH/NIAID (U54 AI082973), “PIDTC #6902: A retrospective and cross-sectional analysis of patients treated for SCID” (2017-ongoing), DeSantes, site PI

Children’s Hospital Los Angeles & NIH/NIAID (U54 AI082973), “PIDTC #6903: Analysis of patients treated for chronic granulomatous disease” (2016-ongoing), DeSantes, site PI

Children’s Hospital Los Angeles & NIH/NIAID (U54 AI082973), “PIDTC #6901: A prospective natural history study of diagnosis, treatment and outcomes of children with SCID disorders” (2016-ongoing), DeSantes, site PI

Children’s Hospital of Philadelphia & Seattle Genetics, Inc., “A randomized phase III study of brentuximab vedotin for newly diagnosed classical hodgkin lymphoma in children and adolescents (AHOD1331)” (2016-ongoing). DeSantes, site PI

Mesoblast, “A single-arm, prospective study of remestemcel-L, ex-vivo cultured adult human mesenchymal stromal cells, for the treatment of pediatric patients who have failed to respond to steroid treatment for acute GVHD” (2016-ongoing). DeSantes, PI

Macrogenics, “UW16107: A phase 1, open-label, dose escalation study of MGA271 in pediatric patients with B7-H3-expressing relapsed or refractory solid tumors” (2016-ongoing). DeSantes, PI

Boehringer Ingelheim, Ltd., “Phase I open label, dose escalation trial to determine the MTD, safety, PK and efficacy of afatinib monotherapy in children aged 2 years to <18 years with recurrent/refractory neuroectodermal tumours, rhabdomyosarcoma and/or other solid tumours” (2016-ongoing). Patel, PI

Nationwide Children’s Hospital, “The "head start 4" protocol newly diagnosed children (less than 10 years old) with medulloblastoma and other central, nervous system embryonal tumors, phase IV” (2015-ongoing). Patel, site PI

Children’s Hospital of Philadelphia & Children’s Oncology Group, “Everychild protocol: a registry, eligibility screening, biology and outcome study (APEC14B1)” (2015-ongoing). DeSantes, PI

Children’s Hospital of Philadelphia & Hoffmann-LaRoche, Inc., “Intergroup trial for children or adolescents with B-cell NHL or B-AL: evaluation of rituximab efficacy and safety in high risk patients (ANHL1131)” (2014-ongoing). DeSantes, PI

Children’s Hospital of Philadelphia, “AALL1131 - A phase III randomized trial for newly diagnosed high risk B-precursor acute lymphoblastic leukemia testing clofarabine in the very high risk stratum (AALL1131)” (2014-ongoing). DeSantes, PI

Solving Kids Cancer, “Phase I trial of ex-vivo expanded haploidentical NK cells and Hu14.18-IL2 for children with relapsed/refractory neuroblastoma” (2012-2017). DeSantes, PI

Children’s Hospital of Philadelphia & Bristol-Myers Squibb Company, “A phase 2 multi-center, historically-controlled study of dasatinib added to standard chemotherapy in pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia” (2012-ongoing). DeSantes, site PI

Children’s Hospital of Philadelphia & Millenium Pharmaceuticals, “A phase III randomized trial for patients with de novo AML using bortezomib and sorafenib for patients with high allelic ratio FLT2/ITD (AAML1031)” (2012-ongoing). DeSantes, site PI